Nurix Therapeutics, Inc. NRIX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
1.2
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $84.0M | -$264.5M | — | -$263.5M | $538.7M |
| 2024 | $54.5M | -$193.6M | — | -$181.9M | $527.0M |
| 2023 | $77.0M | -$143.9M | — | -$89.8M | $200.5M |
| 2022 | $38.6M | -$180.4M | — | -$172.1M | $303.7M |
| 2021 | $29.8M | -$117.2M | — | -$90.0M | $342.3M |
| 2020 | $17.8M | -$43.2M | — | -$4.6M | $290.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.2 (grey)
- Working capital / assets 0.756
- Retained earnings / assets -1.458
- EBIT / assets -0.415
- Equity / liabilities 3.606
Source: SEC EDGAR filings · CIK 0001549595 · as of 2025-11-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.